Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
49
GALT Quote, Financials, Valuation and Earnings
Last price:
$6.31
Seasonality move
:
33.36%
Day range:
$5.72 - $6.52
52-week range:
$0.73 - $6.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
743.9K
Avg. volume:
396.9K
1-year change:
167.52%
Market cap:
$406.2M
Revenue:
--
EPS (TTM):
-$0.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GALT
Galectin Therapeutics, Inc.
|
-- | -- | -- | -- | $6.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GALT
Galectin Therapeutics, Inc.
|
$6.30 | $6.00 | $406.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
NNVC
NanoViricides, Inc.
|
$1.22 | $7.00 | $22M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.85 | $2.00 | $700.8K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.24 | $7.00 | $8.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GALT
Galectin Therapeutics, Inc.
|
-9646.06% | 4.898 | 44.44% | 0.08x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GALT
Galectin Therapeutics, Inc.
|
-- | -$4.2M | -1425.85% | -- | -- | -$3.5M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Galectin Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns GALT or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Galectin Therapeutics, Inc.'s net margin of -255.85%. Galectin Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital GALTGalectin Therapeutics, Inc.-- -$0.13 -$1.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About GALT or NBY?
Galectin Therapeutics, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4.76%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that NovaBay Pharmaceuticals, Inc. has more downside risk than Galectin Therapeutics, Inc., analysts believe Galectin Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GALTGalectin Therapeutics, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is GALT or NBY More Risky?
Galectin Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock GALT or NBY?
Galectin Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Galectin Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALT or NBY?
Galectin Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Galectin Therapeutics, Inc.'s net income of -$8.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Galectin Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics, Inc. is -- versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALTGalectin Therapeutics, Inc.-- -- -- -$8.2M NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns GALT or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Galectin Therapeutics, Inc.'s net margin of --. Galectin Therapeutics, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital GALTGalectin Therapeutics, Inc.-- -$0.13 -$1.3M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About GALT or NNVC?
Galectin Therapeutics, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4.76%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 473.77%. Given that NanoViricides, Inc. has higher upside potential than Galectin Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than Galectin Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GALTGalectin Therapeutics, Inc.1 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is GALT or NNVC More Risky?
Galectin Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock GALT or NNVC?
Galectin Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALT or NNVC?
Galectin Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Galectin Therapeutics, Inc.'s net income of -$8.2M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Galectin Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALTGalectin Therapeutics, Inc.-- -- -- -$8.2M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns GALT or OGEN?
Oragenics, Inc. has a net margin of -- compared to Galectin Therapeutics, Inc.'s net margin of --. Galectin Therapeutics, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital GALTGalectin Therapeutics, Inc.-- -$0.13 -$1.3M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About GALT or OGEN?
Galectin Therapeutics, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4.76%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 134.85%. Given that Oragenics, Inc. has higher upside potential than Galectin Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Galectin Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GALTGalectin Therapeutics, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is GALT or OGEN More Risky?
Galectin Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock GALT or OGEN?
Galectin Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALT or OGEN?
Galectin Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Galectin Therapeutics, Inc.'s net income of -$8.2M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Galectin Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALTGalectin Therapeutics, Inc.-- -- -- -$8.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns GALT or PTN?
Palatin Technologies has a net margin of -- compared to Galectin Therapeutics, Inc.'s net margin of --. Galectin Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GALTGalectin Therapeutics, Inc.-- -$0.13 -$1.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About GALT or PTN?
Galectin Therapeutics, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4.76%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Galectin Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Galectin Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GALTGalectin Therapeutics, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is GALT or PTN More Risky?
Galectin Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock GALT or PTN?
Galectin Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALT or PTN?
Galectin Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Galectin Therapeutics, Inc.'s net income of -$8.2M is higher than Palatin Technologies's net income of --. Notably, Galectin Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALTGalectin Therapeutics, Inc.-- -- -- -$8.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns GALT or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Galectin Therapeutics, Inc.'s net margin of --. Galectin Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital GALTGalectin Therapeutics, Inc.-- -$0.13 -$1.3M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About GALT or TOVX?
Galectin Therapeutics, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4.76%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Galectin Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Galectin Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GALTGalectin Therapeutics, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is GALT or TOVX More Risky?
Galectin Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock GALT or TOVX?
Galectin Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALT or TOVX?
Galectin Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Galectin Therapeutics, Inc.'s net income of -$8.2M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Galectin Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALTGalectin Therapeutics, Inc.-- -- -- -$8.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 171.49% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 0.01% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 4.15% over the past day.
